<DOC>
	<DOCNO>NCT00002552</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining bone marrow transplantation chemotherapy may allow doctor give high dos chemotherapy kill tumor cell . PURPOSE : This phase II trial study side effect give bone marrow transplant together chemotherapy see well work treat patient refractory non-Hodgkin 's lymphoma , Hodgkin 's lymphoma , multiple myeloma .</brief_summary>
	<brief_title>Chemotherapy Plus Bone Marrow Transplantation Treating Patients With Refractory Non-Hodgkin 's Lymphoma , Hodgkin 's Disease , Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I. Assess toxicity , response rate , duration response associate high-dose cyclophosphamide , etoposide , carmustine high-dose cyclophosphamide total-body irradiation follow autologous , allogeneic , syngeneic bone marrow transplant patient refractory high-risk non-Hodgkin 's lymphoma , Hodgkin 's disease , multiple myeloma . II . Evaluate prognostic factor . OUTLINE : Patients prior radiotherapy ( great 2,000 cGy ) receive cyclophosphamide IV 2 hour etoposide IV least 30 minute day -7 -4 follow carmustine IV 2 hour day -3 . Patients receive allogeneic autologous bone marrow transplantation day 0 . Patients without prior radiotherapy ( le 2,000 cGy ) receive cyclophosphamide IV 2 hour day -8 -5 follow total body irradiation day -4 -1 . Patients receive allogeneic autologous bone marrow transplantation day 0 . Prior autologous bone marrow transplantation follow myeloablative chemotherapy , patient undergo mobilization consist cytarabine subcutaneously every 12 hour 6 dos . Approximately 24 hour later , patient receive sargramostim ( GM-CSF ) subcutaneously . Peripheral blood stem cell collect every 1-3 day begin blood count recover continue sufficient number cell reach . PROJECTED ACCRUAL : Approximately 40 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove Hodgkin 's disease ( HD ) , nonHodgkin 's lymphoma ( NHL ) , multiple myeloma ( MM ) meeting follow requirement : Refractory high risk follow prior therapy Responded least partial response last cytoreductive regimen No bulky disease ( individual tumor diameter large 5 cm ) Eligible HD : CNS involvement original presentation currently complete response ( CR ) Relapsed within 1 year follow completion frontline MOPP ABVD Relapsed time follow frontline MOPP/ABVD hybrid Eligible NHL : Any grade lymphoma CNS involvement original presentation currently CR Highgrade lymphoma ( International Working Formulation HJ ) marrow involvement original presentation currently CR , EXCEPT : Immunoblastic lymphoma large cell ( IWF G H ) bone marrow involvement small cleave cell original presentation High/intermediategrade lymphoma ( IWF DJ ) relapse adequate frontline therapy High/intermediategrade lymphoma ( IWF DJ ) fail achieve CR adequate frontline therapy Lowgrade lymphoma ( IWF AC ) B symptoms original presentation relapse frontline therapy Lowgrade lymphoma ( IWF AC ) relapse within 1 year follow last chemotherapy Lowgrade lymphoma ( IWF AC ) document histologic conversion Eligible MM : Diagnosis base either presence Group I diagnostic criterion OR One Group I criterion Group II criterion Group I diagnostic criterion : Plasma cell and/or myeloma cell great 10 % bone marrow Biopsyproven plasmacytoma bone soft tissue Group II diagnostic criterion : Monoclonal serum protein spike Urinary myeloma protein Osteolytic lesion radiologic examination Generalized osteoporosis suffices plasma cell marrow exceed 30 % Myeloma cell least 2 peripheral blood smear Stage II/III disease document sometime clinical course Stage III define presence least 1 follow : Hemoglobin le 8.5 g/dl Serum calcium great 12 mg/dl Advanced lytic bone lesion High Mcomponent production rate : IgG great 7 g/dl IgA great 5 g/dl Urinary light chain great 4 g/24 hour Stage II disease define absence Stage III characteristic presence least 1 follow : Hb le 10 g/dl More 1 osteolytic lesion , none advance IgG great 5 g/dl IgA great 3 g/dl Bone marrow donor available lymphoma patient marrow involvement Perfosfamidepurged autologous transplant allow patient match sibling donor : Marrow involvement limit ( less 30 % tumor cell smear bilateral iliac crest biopsy ) AND Age 60 Donor requirement : Excellent physical condition history , lab study , PE No physiologic , psychologic , medical inability tolerate procedure No increase anesthetic risk No HIV infection Priority multiple donor ( order give ) : ABO compatible Age 18 Same sex recipient A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 70 Performance status : 02 Life expectancy : No severe limitation due nonmalignant disease Hematopoietic : Not specify Hepatic : No severe hepatic disease Bilirubin great 2.0 mg/dL Transaminases great 3 time normal Renal : No severe renal disease Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic cardiac disease LVEF least 50 % Pulmonary : No severe pulmonary disease FEV1 FVC least 75 % normal Other : No history severe cystitis cyclophosphamide No HIV infection No severe personality disorder severe mental illness No condition would markedly increase morbidity mortality transplantation ( e.g. , substance abuse ) Patients borderline parameter organ function , performance status , mental status enter discretion transplant team PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult unfavorable prognosis Hodgkin lymphoma</keyword>
	<keyword>childhood unfavorable prognosis Hodgkin lymphoma</keyword>
</DOC>